Claim your 30% discount on Global Market Reports with code ONLINE30. Limited time only.

How Has the Idiopathic Pulmonary Fibrosis Market Size Changed, over the years?

In the past few years, the idiopathic pulmonary fibrosis market has experienced significant growth. It is projected to increase from $4.15 billion in 2024 to $4.39 billion in 2025, achieving a compound annual growth rate (CAGR) of 5.6%. The impressive growth during the historic period can be associated with factors such as the rising aging population, limited alternatives for treatment, heightened disease awareness, and advancements in the healthcare infrastructure.

How Much Will the Idiopathic Pulmonary Fibrosis Market Be Worth in 2029?

The market size for idiopathic pulmonary fibrosis is anticipated to experience significant expansion in the coming years, expected to reach a value of $5.74 billion in 2029, with a compound annual growth rate (CAGR) of 7.0%. This predicted growth during the forecast period is due to particular factors such as intensified research and development, growth in disease incidence, improvements in biomarker development, the precision medicine approach, along with government initiatives and funding. The coming period will see some key trends including developments in diagnostic techniques, the rise of targeted therapies, telemedicine and remote monitoring, combination therapies, and advancements in lung transplantation techniques.

Download The Free Sample Report Here:

https://www.thebusinessresearchcompany.com/sample.aspx?id=12579&type=smp

Which is the Largest Company in the Idiopathic Pulmonary Fibrosis Market?

Major companies operating in the idiopathic pulmonary fibrosis market include F. Hoffmann-La Roche Ltd., Merck & Co. Inc., Novartis AG, Bristol-Myers Squibb Company, AstraZeneca PLC, Sanofi S.A., Gilead Sciences Inc., Toray Industries Inc., Boehringer Ingelheim International GmbH, Viatris Inc., Sun Pharmaceutical Industries Limited, Shionogi and Co. Ltd., Cipla Inc., Zydus Lifesciences Ltd., Chong Kun Dang Pharmaceutical Corp., Kyorin Pharmaceutical Co. Ltd., Galapagos NV, Veracyte Inc., Genentech Inc., FibroGen Inc., GNI Group Ltd., Pliant Therapeutics Inc., Pulmatrix Inc., Galimedix Therapeutics Inc., Avalyn Pharma Inc., MediciNova Inc., Liminal BioSciences Inc., Beijing Continent Pharmaceuticals Company, Galecto Inc.

What Are the Main Market Drivers in the Idiopathic Pulmonary Fibrosis Industry?

The increase in the occurrence of fibrotic disease is predicted to boost the idiopathic pulmonary fibrosis market’s growth. Fibrotic diseases, also referred to as fibrosis, encompass a range of health conditions marked by the excessive development and buildup of fibrous connective tissue in different organs or tissues within the body. Drugs for idiopathic pulmonary fibrosis work to lessen lung fibrosis and inflammation by targeting various signaling pathways associated with fibrosis. For example, as reported by the American Lung Association, a US-based lung organization, in December 2022, there were about 207,000 identified cases in the United States, with nearly 58,000 new diagnoses of idiopathic pulmonary fibrosis each year. This disease predominantly afflicts men over women and is mostly seen in individuals over 50 years of age. Consequently, the increased prevalence of fibrotic disease propels the idiopathic pulmonary fibrosis market.

Request For A Customized Report:

https://www.thebusinessresearchcompany.com/customise?id=12579&type=smp

How Is the Idiopathic Pulmonary Fibrosis Market Segments Structured?

The idiopathic pulmonary fibrosis market covered in this report is segmented –

1) By Drug Type: Nintedanib, Pirfenidone, Other Drug Types

2) By Mode Of Action: Antifibrotic Agents, Tyrosine Kinase Inhibitors, Other Modes Of Action

3) By Route Of Administration: Oral, Parenteral

4) By Distribution Channel: Hospital Pharmacies, Retail Pharmacies, Online Providers

5) By End Users: Hospitals And Clinics, Other End Users

Subsegments:

1) By Nintedanib: Indications, Dosage Forms, Administration Routes

2) By Pirfenidone: Indications, Dosage Forms, Administration Routes

3) By Other Drug Types: Specific Agents Or Classes, Emerging Therapies, Combination Therapies

What Strategic Trends Are Transforming the Idiopathic Pulmonary Fibrosis Market?

The idiopathic pulmonary fibrosis market is witnessing a significant trend in the form of product innovation as major companies strive to enhance their market presence and competitive edge. One such example occurred in May 2022, when Switzerland’s Sandoz, a company specializing in generic and biosimilar medicines, introduced a generic variant of pirfenidone. This was the first AB-rated substitute for Genentech’s Esbriet and was designed to aid those struggling with idiopathic pulmonary fibrosis (IPF). This prescription drug, which is delivered orally, can now be accessed by patients via specialty pharmacies. Moreover, qualifying patients have the added advantage of a USD 0 co-payment program.

Access The Full Report Here:

https://www.thebusinessresearchcompany.com/report/idiopathic-pulmonary-fibrosis-global-market-report

Which Global Regions Offer the Highest Growth in the Idiopathic Pulmonary Fibrosis Market?

North America was the largest region in the idiopathic pulmonary fibrosis market in 2024. Asia Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the idiopathic pulmonary fibrosis market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa

Purchase The Full Report Today:

https://www.thebusinessresearchcompany.com/purchaseoptions.aspx?id=12579

This Report Delivers Insight On:

1. How big is the idiopathic pulmonary fibrosis market, and how is it changing globally?

2. Who are the major companies in the idiopathic pulmonary fibrosis market, and how are they performing?

3. What are the key opportunities and risks in the idiopathic pulmonary fibrosis market right now?

4. Which products or customer segments are growing the most in the idiopathic pulmonary fibrosis market?

5. What factors are helping or slowing down the growth of the idiopathic pulmonary fibrosis market?

About The Business Research Company:

With over 15000+ reports from 27 industries covering 60+ geographies, The Business Research Company has built a reputation for offering comprehensive, data-rich research and insights. Armed with 1,500,000 datasets, the optimistic contribution of in-depth secondary research, and unique insights from industry leaders, you can get the information you need to stay ahead in the game.

Get in touch with us:

The Business Research Company: https://www.thebusinessresearchcompany.com/

Americas +1 3156230293

Asia +44 2071930708

Europe +44 2071930708

Email us at info@tbrc.info

Follow us on:

LinkedIn: https://in.linkedin.com/company/the-business-research-company

YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ

Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model